Expression of EpCAM and prognosis in early-stage glottic cancer treated by radiotherapy

Laryngoscope

Volumn 124, Issue 11, 2014, Pages E431-E436

  Murakami, Naoya ^a   Mori, Taisuke ^a   Yoshimoto, Seiichi ^a   Ito, Yoshinori ^a   Kobayashi, Kazuma ^a   Ken, Harada ^a   Kitaguchi, Mayuka ^a   Sekii, Shuhei ^a   Takahashi, Kana ^a   Yoshio, Kotaro ^a   Inaba, Koji ^a   Morota, Madoka ^a   Sumi, Minako ^a   Itami, Jun ^a  

^a NATIONAL CANCER CENTER HOSPITAL   (Japan)

Author keywords

BerEP4; early stage glottic cancer; EpCAM; Head and neck squamous cell carcinoma; radiation therapy

Indexed keywords

EPITHELIAL CELL ADHESION MOLECULE; CELL ADHESION MOLECULE; TUMOR ANTIGEN; TUMOR MARKER; TUMOR-ASSOCIATED ANTIGEN GA733;

ADULT; AGED; ARTICLE; CANCER INCIDENCE; CANCER OF UNKNOWN PRIMARY SITE; CANCER PATIENT; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER STAGING; CONTROLLED STUDY; EARLY CANCER; FEMALE; FOLLOW UP; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HYPOPHARYNX; INVESTIGATIVE PROCEDURES; LARYNX; LARYNX CANCER; MAJOR CLINICAL STUDY; MALE; MEDICAL EXAMINATION; MOUTH CAVITY; NASOPHARYNX; OROPHARYNX; PARANASAL SINUS; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; CARCINOMA, SQUAMOUS CELL; COHORT ANALYSIS; DISEASE FREE SURVIVAL; EARLY DIAGNOSIS; GENETICS; GLOTTIS; IMMUNOHISTOCHEMISTRY; LARYNGEAL NEOPLASMS; METABOLISM; MIDDLE AGED; MORTALITY; NEEDLE BIOPSY; NEOPLASM RECURRENCE, LOCAL; PATHOLOGY; PROGNOSIS; RADIATION DOSE; RISK ASSESSMENT; SURVIVAL; TREATMENT OUTCOME; TUMOR INVASION; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTIGENS, NEOPLASM; BIOPSY, NEEDLE; CARCINOMA, SQUAMOUS CELL; CELL ADHESION MOLECULES; COHORT STUDIES; DISEASE-FREE SURVIVAL; EARLY DETECTION OF CANCER; FEMALE; GLOTTIS; HUMANS; IMMUNOHISTOCHEMISTRY; LARYNGEAL NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; RADIOTHERAPY DOSAGE; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SURVIVAL ANALYSIS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84922325914     PISSN: 0023852X     EISSN: 15314995     Source Type: Journal    
DOI: 10.1002/lary.24839     Document Type: Article

References (26)

1. Forastiere AA, Goepfert H, Maor M, et al., Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med 2003; 349: 2091-2098.
2. Adelstein DJ, Li Y, Adams GL, et al., An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. J Clin Oncol 2003; 21: 92-98.
3. Cooper JS, Pajak TF, Forastiere AA, et al., Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N Engl J Med 2004; 19: 1937-1944.
4. Ang KK, Berkey BA, Tu X, et al., Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. Cancer Res 2002; 62: 7350-7356.
5. Dassonville O, Formento JL, Francoual M, et al., Expression of epidermal growth factor receptor and survival in upper aerodigestive tract cancer. J Clin Oncol 1993; 11: 1873-1878.
6. Couture C, Raybaud-Diogène H, Têtu B, et al., p53 and Ki-67 as markers of radioresistance in head and neck carcinoma. Cancer 2002; 94: 713-722.
7. Lassen P,. The role of human papillomavirus in head and neck cancer and the impact on radiotherapy outcome. Radiother Oncol 2010; 95: 371-380.
8. Lindel K, Beer KT, Laissue J, Greiner RH, Aebersold DM,. Human papillomavirus positive squamous cell carcinoma of the oropharynx: a radiosensitive subgroup of head and neck carcinoma. Cancer 2001; 92: 805-813.
9. Lassen P, Overgaard J, Eriksen JG,. Expression of EGFR and HPV-associated p16 in oropharyngeal carcinoma: correlation and influence on prognosis after radiotherapy in the randomized DAHANCA 5 and 7 trials. Radiother Oncol 2013; 108: 489-494.
10. Okegawa T, Pong RC, Li Y, Hsieh JT,. The role of cell adhesion molecule in cancer progression and its application in cancer therapy. Acta Biochim Pol 2004; 51: 445-457.
11. Trzpis M, McLaughlin PM, de Leij LM, Harmsen MC,. Epithelial cell adhesion molecule: more than a carcinoma marker and adhesion molecule. Am J Pathol 2007; 171: 386-395.
12. Bellone S, Siegel ER, Cocco E, et al., Overexpression of epithelial cell adhesion molecule in primary, metastatic, and recurrent/chemotherapy-resistant epithelial ovarian cancer: implications for epithelial cell adhesion molecule-specific immunotherapy. Int J Gynecol Cancer 2009; 19: 860-866.
13. Diaz-Arias AA, Loy TS, Bickel JT, Chapman RK,. Utility of BER-EP4 in the diagnosis of adenocarcinoma in effusions: an immunocytochemical study of 232 cases. Diagn Cytopathol 1993; 9: 516-521.
14. Saadatmand S, de Kruijf EM, Sajet A, et al., Expression of cell adhesion molecules and prognosis in breast cancer. Br J Surg 2013; 100: 252-260.
15. Stoecklein NH, Siegmund A, Scheunemann P, et al., Ep-CAM expression in squamous cell carcinoma of the esophagus: a potential therapeutic target and prognostic marker. BMC Cancer 2006; 6: 165-172.
16. Imadome K, Iwakawa M, Nakawatari M, et al., Subtypes of cervical adenosquamous carcinomas classified by EpCAM expression related to radiosensitivity. Cancer Biol Ther 2010; 10: 1019-1026.
17. Barnes L, Everson JW, Reichart P, Sidransky D,. Pathology and Genetics: Head and Neck Tumors. World Health Organization Classification of Tumours. Lyon, France: International Agency for Research on Cancer Press; 2005.
18. Patriarca C, Macchi RM, Marschner AK, Mellstedt H,. Epithelial cell adhesion molecule expression (CD326) in cancer: a short review. Cancer Treat Rev 2012; 38: 68-75.
19. Nylander K, Nilsson P, Mehle C, Roos G,. p53 mutations, protein expression and cell proliferation in squamous cell carcinomas of the head and neck. Br J Cancer 1995; 71: 826-830.
20. Muller PA, Vousden KH,. p53 mutations in cancer. Nat Cell Biol 2013; 15: 2-8.
21. Schache AG, Liloglou T, Risk JM, et al., Evaluation of human papilloma virus diagnostic testing in oropharyngeal squamous cell carcinoma: sensitivity, specificity, and prognostic discrimination. Clin Cancer Res 2011; 17: 6262-6271.
22. Sobin LH, Gospodarowicz MK, Wittekind C, eds. UICC: TNM Classification of Malignant Tumors. 7th ed. New York, NY: Wiley Periodicals, 2009.
23. Franchin G, Minatel E, Gobitti C, et al., Radiotherapy for patients with early-stage glottic carcinoma: univariate and multivariate analyses in a group of consecutive, unselected patients. Cancer 2003; 98: 765-772.
24. Le QT, Fu KK, Kroll S, et al., Influence of fraction size, total dose, and overall time on local control of T1-T2 glottic carcinoma. Int J Radiat Oncol Biol Phys 1997; 39: 115-126.
25. Romeu C, Farré X, Cardesa A, et al., Expression of Ep-CAM, but not of E48, associates with nodal involvement in advanced squamous cell carcinomas of the larynx. Histopathology 2013; 62: 654-961.
26. Okunieff P, Augustine E, Hicks JE, et al., Pentoxifylline in the treatment of radiation-induced fibrosis. J Clin Oncol 2004; 22: 2207-2213.